Kamada Ltd
NASDAQ:KMDA
Kamada Ltd
NASDAQ:KMDA
Price:
8.5
USD
-1.39%
Market Closed
Market Cap:
$490.3m
Kamada Ltd
Other Items
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Kamada Ltd
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Other Items
$8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-46%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Other Items
$11.5m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Other Items
$61.8m
|
CAGR 3-Years
261%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Other Items
$7.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Other Items
₪9.9m
|
CAGR 3-Years
635%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
KMDA
Intrinsic Value
7.92
USD
Overvaluation 7%
See Also
What is Kamada Ltd's Other Items?
Other Items
8k
USD
8k
USD
Based on the financial report for Sep 30, 2025, Kamada Ltd's Other Items amounts to 8k USD.
What is Kamada Ltd's Other Items growth rate?
Other Items CAGR 10Y
-46%
-46%
